Ronald C. Renaud JR - 03 Aug 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: President & CEO, Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: CERE
Transactions as of: 03 Aug 2023
Transactions value $: $2,008,811
Form type: 4
Date filed: 07 Aug 2023, 17:13
Previous filing: 14 Jun 2023
Next filing: 21 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Purchase	$2.01M	+83.9K		$23.96	83.9K	03 Aug 2023	By Trust	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.78 - $24.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

Content

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.78 - $24.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.